about
HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory DiseasesAction mechanisms of histone deacetylase inhibitors in the treatment of hematological malignanciesThe multifaceted role of lysine acetylation in cancer: prognostic biomarker and therapeutic targetUnexploited Antineoplastic Effects of Commercially Available Anti-Diabetic DrugsInhibition of histone deacetylases in cancer therapy: lessons from leukaemiaDelaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerMutant p53: One, No One, and One Hundred ThousandPotential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?Potential of epigenetic therapies in the management of solid tumorsBelinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective reviewHistone Deacetylases Exert Class-Specific Roles in Conditioning the Brain and Heart Against Acute Ischemic InjuryOrchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not DestructionAccessing DNA damage in chromatin: Preparing the chromatin landscape for base excision repairGenetic and epigenetic factors influencing chronic kidney diseaseNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewNeuroprotection, Growth Factors and BDNF-TrkB Signalling in Retinal DegenerationEpigenetic modulators as therapeutic targets in prostate cancerEpigenetic Therapeutics: A New Weapon in the War Against CancerAcetylation Reader Proteins: Linking Acetylation Signaling to Genome Maintenance and CancerEpigenetics in Cancer: A Hematological PerspectiveEpigenetic Regulation of Bone Remodeling and Its Impacts in OsteoporosisTrial Watch: Proteasomal inhibitors for anticancer therapyIdentification of HDAC Inhibitors Using a Cell-Based HDAC I/II AssayBifunctional Conjugates with Potent Inhibitory Activity Towards Cyclooxygenase and Histone DeacetylaseHistone acetyltransferase inhibitors block neuroblastoma cell growth in vivoExome-Scale Discovery of Hotspot Mutation Regions in Human Cancer Using 3D Protein Structure.Benchmarking methods and data sets for ligand enrichment assessment in virtual screening.Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trialPhase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia.Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II studySuberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cellsAdvances in epigenetic glioblastoma therapy.Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic RadiotherapyB1, a novel HDAC inhibitor, induces apoptosis through the regulation of STAT3 and NF-κB.Targeting CD146 in combination with vorinostat for the treatment of ovarian cancer cells.Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancerA Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC.Prognostic Biomarker Identification Through Integrating the Gene Signatures of Hepatocellular Carcinoma PropertiesSynergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms
P2860
Q26739120-1AA6F4F9-5CE6-45A0-A6DB-1C7BEBB7C63FQ26739689-2370507E-0B1C-49A8-8839-335F74F72F97Q26744292-E696FAE1-A276-4325-84BE-7DD4405F071AQ26750845-F5D8670D-0C9E-43F8-9519-EB337CFDBEBEQ26767024-7A4F6A02-4D46-4C26-ADD3-3B8E816693C9Q26770482-E07CFCD6-63B0-48D8-B699-E213F1EF3D72Q26770576-B009BBEE-2341-4893-BC72-32F25E063916Q26771601-A94A8772-93A3-48BD-ACA3-5E9A089DAE5AQ26783134-96F1463C-19FB-4485-97EF-B86CA2D3EFDBQ26796449-4F384224-56DE-446F-A182-D4E15E56945FQ26801660-0F707193-C621-4434-93FD-A91B0B91F4ACQ26801834-58884B35-ABB8-4080-831C-4F256E880A44Q26828361-0060153F-02D0-4E4B-A391-CC5D4475D1A7Q27024548-08ABBCA2-6BBC-415D-A85C-5E60C4C88E34Q27304386-EFA542B4-51AE-4646-A369-7E25B1F7473BQ28069477-8E77ECCF-D8A8-472C-9127-F0836F8F06C7Q28071912-46376B81-1EAA-422A-8378-FCD0E3D5A44AQ28072370-DC2EDA86-EB48-4678-BEB1-9371E6009231Q28076086-7F87DC4C-B9E4-4724-B636-1BB6F7F9E3B5Q28077082-F2DC3DAB-67FA-4B6E-81C7-D6CCD90F2C6FQ28077554-09D55612-7E31-4D8E-87EF-18F61531DA42Q28082910-54B56C41-2C04-481B-B765-A5C38BB85179Q28829359-71A9528E-9915-4E30-8197-F5A6C4E74911Q29248227-56CFA292-D163-4E4E-B926-2ED824885313Q30316789-B104340D-E6E1-4AE3-9324-CCF29FCFDED2Q30388270-5A79F407-4225-4D92-A25C-B36C50F07659Q30875193-87D05593-A00D-4D09-BD7D-4400A4765E86Q33431267-6222E9D6-0F73-4714-950F-3B8A0745F5EEQ33437309-42EC1D1C-49F0-49F4-B083-EC897980A36CQ33438732-5C157ED4-0A28-4CA9-AE1D-72D4517E12F5Q33566645-0C5AF6EC-2D51-4C1A-98CF-C61E41E2009EQ33567030-106A8E45-08FD-413A-8A6B-32756CFB2845Q33584050-3CA21B29-615A-40A7-84EB-25D55664FCCCQ33597695-97BFD9AB-D87F-4D2B-8D11-19FC645D1CC2Q33598464-106EB1B7-9528-4F82-846D-7BE60FD10737Q33649853-31221383-E704-429B-A0BE-3E51B75CE4FDQ33659166-70C94105-0D15-4E7D-9E31-AF7B33139700Q33689457-AF5071FE-7DF7-484E-9E0B-0C760D545CD2Q33715750-189A2C35-5094-43C6-8439-E6E730440D02Q33761796-E8A80D0B-CF10-41CD-9053-DA5FB8F02A27
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
New and emerging HDAC inhibitors for cancer treatment
@ast
New and emerging HDAC inhibitors for cancer treatment
@en
New and emerging HDAC inhibitors for cancer treatment
@nl
type
label
New and emerging HDAC inhibitors for cancer treatment
@ast
New and emerging HDAC inhibitors for cancer treatment
@en
New and emerging HDAC inhibitors for cancer treatment
@nl
prefLabel
New and emerging HDAC inhibitors for cancer treatment
@ast
New and emerging HDAC inhibitors for cancer treatment
@en
New and emerging HDAC inhibitors for cancer treatment
@nl
P2860
P3181
P356
P1476
New and emerging HDAC inhibitors for cancer treatment
@en
P2093
Alison C. West
P2860
P3181
P356
10.1172/JCI69738
P407
P577
2014-01-01T00:00:00Z